UnitedHealth Q1 2026: 83.9% MBR Resets the Medical Trend Debate

UnitedHealth Group reported first quarter 2026 results on April 22 with a consolidated medical benefit ratio of 83.9 percent, roughly 180 basis points inside the 85.7 percent FactSet consensus. Management lifted the low end of the full-year adjusted EPS guide from $17.75 to $18.25 and reaffirmed the $18.75 ceiling.

The beat is not the interesting part. The interesting part is that 2026 pricing, locked last June on a roughly 10 percent Medicare Advantage rate action against a 7 to 8 percent trend assumption, is holding one quarter into the year every model had coded as the riskiest trend environment since 2009.

Key Takeaways

• 180 basis points inside consensus, of which roughly 100 to 120 is recurring pricing and trend discipline and 50 to 70 is non-recurring prior-period development on Optum value-based care runout.
• 7.5 percent realized MA trend against a 7 to 8 percent planning assumption, which is inside the range rather than below it. Nothing here argues for resetting sector trend below 7.
• 200 to 250 basis points of gross MA margin expansion for 2026 if the rate action holds on a revenue-weighted basis, of which 60 to 80 reaches the consolidated MBR.
• The 960 basis point gap to Elevance's 93.5 percent Q4 2025 print is book mix, not pricing skill. On MA segment alone the gap is closer to 300 to 400 basis points.
• 2.48 percent finalized for CY2027 against a 7 to 8 percent trend planning band, a materially narrower cushion than 2026 gave.

What the 180 Basis Points Contained

UNH printed 85.1 percent for full-year 2024 and ran 84.5 to 85.0 percent across the four quarters of 2025, so the year-over-year comparison is favorable by 30 to 60 basis points depending on the Q1 2025 reference used. The consensus beat is the larger and more actionable figure.

Management flagged three separable drivers on the call. The 2026 MA pricing action landed at the high end of the 9 to 10 percent range signalled at the June 2025 investor day. Medical trend in the MA book ran around 7.5 percent, inside the 7 to 8 percent planning assumption. And the quarter carried favorable prior-period development on 2025 claim runout, concentrated in the Optum Health value-based care contracts behind the Q3 and Q4 2024 MBR blowout.

The split is what matters. Roughly 100 to 120 basis points is pricing and trend discipline that recurs; 50 to 70 basis points is reserve release that does not. Whether Q2 and Q3 revert toward the 84.5 to 85.0 band UNH printed in 2025 or hold at 83.5 to 84.5 depends entirely on which half was doing the work.

The reserve release itself splits two ways. Redundancy on a block that was underpriced in a prior year is the normal unwinding of conservative provisions taken during a loss-recognition cycle, which is what the Optum Health contracts look like. Redundancy on a block priced tightly that then ran favorably is a different signal, and that is closer to what the core MA book shows.

The Cushion Is Real and Front-Loaded

Translating a 10 percent rate action against 7.5 percent realized trend into margin is where the 2026 thesis lives, and the answer is sensitive to when in the year you measure it.

On a revenue-weighted basis, a rate action holding at that level against trend printing at the low end of the planning range produces 200 to 250 basis points of gross MA margin expansion for 2026 over 2025. Benefit generosity on retained lives absorbs some of it, since MA buyers are sensitive to supplemental benefit compression. Stars reinvestment and Optum Health value-based contract resets absorb more. What drops to the consolidated MBR is the 60 to 80 basis points of favorability the Q1 print shows against where 2025 settled.

The cushion is not evenly distributed across the year. Q1 is structurally the lowest-MBR quarter: commercial deductible resets front-load member cost share, and Part D utilization is light in the opening weeks before members reach the initial coverage phase. Q2 and Q3 typically run 100 to 200 basis points above Q1 on elective surgical volume and the specialty pharmacy pipeline in obesity, oncology and autoimmune indications.

If second-half utilization reverts toward 2025 levels, the 200 to 250 basis point gross cushion compresses to 100 to 150 on a full-year basis. That puts the defensible full-year MBR range at 84.2 to 84.8 percent, margin expansion against 2025 but not a return to the pre-2024 83.0 to 83.5 band the bullish case needs.

The peer comparison is less informative than the spread suggests. UNH at 83.9 percent against Elevance's 93.5 percent Q4 2025 is a 960 basis point gap that is mostly ACA exchange exposure, which UNH has deliberately run smaller for several filing cycles. On MA segment alone, UNH in the mid-84s against Elevance's Medicare book in the high 80s is a 300 to 400 basis point gap, which is a tractable number.

Why 2027 Does Not Inherit This

The 2026 result was produced by a wide gap between rate and trend. The 2027 rate environment does not offer one.

The CMS 2027 MA final rate notice published April 6 finalized a 2.48 percent average effective rate change, up from the 0.09 percent in the January advance notice. The revision came from a 155 basis point increase in the effective growth rate assumption on updated Part A and Part B per-capita spending data, plus 84 basis points from a loosening of the FFS normalization drag.

That is constructive against the advance notice and thin against trend. The 2026 bids cleared a 7 to 8 percent trend assumption on a roughly 10 percent rate action; 2027 asks the same discipline to clear a similar trend band on 2.48 percent plus whatever commercial and Medicaid actions land in the 5 to 7 percent range. The arithmetic that produced the Q1 beat does not repeat.

V28 tightens it further. Phase-in weight rises to 67 percent in 2027 and 100 percent in 2028, so the risk score friction that drove the roughly 350 basis point MA miss in 2024 is still increasing while the rate cushion shrinks. The same dual-eligible and chronic condition populations that stacked V28 friction, GLP-1 specialty pharmacy runway and elective volume normalization on top of each other in 2024 remain the exposure.

Which leaves the run-rate question. Anyone extrapolating the full 180 basis point beat into 2027 is carrying the Optum reserve release forward twice: once as a 2026 earnings event that already happened, and again as a margin level that was never underwritten. As industry commentary on the print noted, the 2024 trend that forced the repricing ran in the high 7s to low 8s, which is where 2027 planning still sits. The Q1 result supports holding trend assumptions in the 7 to 8 percent band for the June bid deadline. It does not support tightening either side of that math.